Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
NASDAQ
$8.01
▼ DOWN 3.03% (-0.25)

KEY STATISTICS

Market Cap$3.58 B
52w High$9.36
52w Low$1.76
Dividend Yield—
Frequency—
P/E-10.97
Volume7.68M
Shares Out.446.50M

COMPANY

LEADERSHIP

Frederick G. Vogt
CHIEF EXECUTIVE
Frederick G. Vogt

COMPENSATION 2026

Salary$800,000
Stock Awards$759,375
Incentive Plan Pay$312,000
All Other Comp.$16,800
Total$1,888,175

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 15, 2010
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
975

PRICE TARGET

Target High$13.00
Target Low$5.00
Target Median$6.50
Target Consensus$7.83

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$110.12M
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2013-09-26Reverse1:100
2010-05-26Forward23999:1000

PRICE

$8.01 ▼ DOWN 3.03% (−$0.25)
OVERLAYS
$8.00$8.10$8.20$8.309:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM8.01

About Iovance Biotherapeutics, Inc.

https://www.iovance.com ↗

Iovance Biotherapeutics is a clinical-stage biotech developing cancer immunotherapies like lifileucel and LN-145, with multiple Phase 2 trials targeting melanoma, cervical, and head and neck cancers.

INDUSTRY

Biotechnology

A PRODUCT IOVANCE BIOTHERAPEUTICS, INC. IS KNOWN FOR

Amtagvi (lifileucel)
Amtagvi (lifileucel)

Amtagvi is the first FDA-approved, one-time, personalized T-cell immunotherapy for adult patients with unresectable or metastatic melanoma, offering a novel treatment approach for solid tumor cancers.

COMPETITORS

COMPETITOR
IMTX COMPARE
LYEL COMPARE

Revenue by Products

IconPRODUCTQ2-2023Q3-2023
Product$200K $500K ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$66.4M $85.49M ▲$70.47M ▼$98.97M ▲
NonUS$1.05M $1.28M ▲$958K ▼$346K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
157
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
1.07% · 15.5M
VTS.AX
0.00% · 13.5M
XSU.TO
0.10% · 10.2M
SCHA
0.06% · 1.8M
FESM
0.18% · 1.4M
DFMC
0.13% · 1.2M
PRFZ
0.30% · 1.0M
AVSC
0.18% · 670.7K
LABU
0.73% · 561.8K
XSXD.L
0.04% · 436.1K
CANC
1.53% · 403.7K
BBP
2.49% · 358.9K
RSSL
0.10% · 190.0K
HY
HYP
2.04% · 178.2K
TILT
0.03% · 74.8K
CN
CNCR
3.47% · 67.5K
WBIO.L
1.30% · 54.3K
GINN
0.12% · 29.2K
RFLR
0.14% · 16.9K
URTY
0.04% · 16.2K
TMFX
0.15% · 6.8K
PWS
0.22% · 6.7K
USFMDN.MX
0.01% · 1.7K
JHMH
0.07% · 1.3K
AESL
0.39% · 940
RESM
0.10% · 759

INSTITUTIONAL OWNERSHIP

SHARES OWNED
45.92%
HOLDERS
399
TOP 12 OF 399 · RANKED BY POSITION SIZE
Blackrock, Inc.
31.1M sh · $109.09M
Mhr Fund Management LLC
29.0M sh · $62.86M
Vanguard Group Inc
27.2M sh · $74.28M
Blackrock Inc.
21.2M sh · $170.23M
State Street Corp
20.2M sh · $55.04M
Bank Of America Corp /De/
14.3M sh · $38.98M
Two Sigma Investments, LP
13.7M sh · $48.04M
Invenomic Capital Management LP
12.0M sh · $32.65M
Millennium Management LLC
9.4M sh · $33.04M
Morgan Stanley
9.2M sh · $25.09M
Long Focus Capital Management, LLC
9.1M sh · $19.78M
Goldman Sachs Group Inc
8.8M sh · $30.75M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF COMMERCIAL OFFICER
Kirby Daniel Gordon
Purchase · 10.0K shares
2026-08-10
★
OFFICER: CHIEF COMMERCIAL OFFICER
Kirby Daniel Gordon
Sale · 2.4K shares
2026-08-10
★
OFFICER: CHIEF COMMERCIAL OFFICER
Kirby Daniel Gordon
Sale · 10.0K shares
2026-08-10
★
OFFICER: CHIEF FINANCIAL OFFICER
Roche Corleen M.
Sale · 50.0K shares
2026-08-06

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
NEUTRAL 1
OUTPERFORM 1
MARKET OUTPERFORM 1
OVERWEIGHT 1
7 GRADES IN THE LAST 12 MONTHS
TD Cowen BUY UBS NEUTRAL Mizuho OUTPERFORM Citizens MARKET OUTPERFORM Barclays OVERWEIGHT Chardan Capital BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
ERAS$18.03COMPARE
MBX$63.00COMPARE
VIR$10.83COMPARE
AVBP$30.17COMPARE
REPL$15.50COMPARE
MGTX$13.82COMPARE
MLTX$14.99COMPARE
CTMX$3.21COMPARE